Skip to main content

Table 1 Patient characteristics

From: Inflammatory cell infiltrates in the heart of patients with coronary artery disease with and without inflammatory rheumatic disease: a biopsy study

Characteristics

IRD (n = 48)

Non-IRD (n = 40)

p Value

Age, years, mean ± SD

66 ± 10

66 ± 11

0.85

Male sex, n (%)

28 (58)

27 (68)

0.45

Duration of CAD, months, median (IQR)

24 (81)

32 (119)

0.39

History of myocardial infarction, n (%)

30 (63)

19 (48)

0.17

Number of myocardial infarctions, mean ± SD

0.8 ± 0.9

0.6 ± 0.8

0.28

NYHA class, mean ± SD

2.9 ± 0.7

2.6 ± 0.6

0.04

Number of coronary arteries with significant stenosis, mean ± SD

2.7 ± 0.6

2.6 ± 0.7

0.44

Acute coronary syndrome, n (%)

12 (25)

10 (25)

0.90

Left ventricular ejection fraction, mean ± SD

64 ± 12

65 ± 11

0.52

Previous heart surgery, n (%)

1 (2.1)

0 (0)

0.73

Positive family history of CAD,a n (%)

33 (69)

31 (78)

0.41

C-reactive protein, mg/L, median (IQR)

4.9 (10.5)

2.1 (2.6)

<0.001

ESR, mm/h, median (IQR)

23 (28)

13 (17)

0.003

Troponin I, ng/ml, median (IQR)

0.06 (0.11)

0.01 (0.04)

0.01

Body mass index, kg/m2, mean ± SD

25 ± 4

26 ± 3

0.58

Hypertension, n (%)

28 (58)

20 (50)

0.46

Current smoker, n (%)

13 (27)

7 (18)

0.26

Previous smoking, n (%)

18 (38)

18 (45)

0.45

Diabetes mellitus, n (%)

6 (13)

5 (13)

0.87

Hypercholesterolemia, n (%)

40 (83)

36 (90)

0.45

Acetylsalicylic acid, n (%)

43 (90)

35 (88)

0.88

ACE inhibitors, n (%)

15 (31)

12 (30)

0.91

Statins, n (%)

37 (77)

32 (80)

0.70

Beta blockers, n (%)

36 (75)

31 (78)

0.71

Disease-modifying antirheumatic drugs,b n (%)

16 (33)

0 (0)

<0.001

Systemic glucocorticosteroids, n (%)

19 (40)

0 (0)

<0.001

Nonsteroidal anti-inflammatory drugs, n (%)

6 (13)

0 (0)

0.018

Cyclooxygenase 2 selective inhibitors, n (%)

8 (17)

0 (0)

0.004

Duration of IRD, years, mean ± SD

17 ± 12

NA

NA

Patient’s global assessment of disease activity,c mean ± SD

3.1 ± 2.5

NA

NA

Physician’s global assessment of disease activity,c mean ± SD

1.4 ± 1.3

NA

NA

  1. Abbreviations: NA Not applicable, CAD coronary artery disease, IRD inflammatory rheumatic disease, NYHA New York Heart Association, ESR erythrocyte sedimentation rate, ACE angiotensin-converting enzyme, IQR interquartile range
  2. Owing to missing data for some variables, numbers may not add up to the expected total
  3. aCAD in first-degree relatives younger than age 65 years
  4. bMethotrexate (n = 6), sulfasalazine (n = 4), hydroxychloroquine (n = 1), azathioprine (n = 1), leflunomide (n = 1), etanercept and methotrexate (n = 1), podofyllotoxine derivatives (CPH-82) (n = 1), hydroxychloroquine and sulfasalazine (n = 1)
  5. cOn a 10-cm visual analogue scale